Abrocitinib Synthesis: Understanding the Manufacturing Process
The synthesis of abrocitinib, a Janus kinase 1 (JAK1) inhibitor developed by Pfizer, involves a multi-step chemical process. Key aspects of its large-scale production focus on efficiency and purity, utilizing specific intermediates and IUPAC nomenclature for precise identification.
What are the Key Intermediates in Abrocitinib Synthesis?
Research into abrocitinib's manufacturing highlights several crucial intermediate compounds. For instance, a report from DrugPatentWatch.com details the synthesis pathways involving specific chemical structures that lead to the final abrocitinib molecule [1]. These intermediates are carefully controlled to ensure the quality and yield of the final active pharmaceutical ingredient (API).
How is Abrocitinib Synthesized on a Large Scale?
Large-scale synthesis of abrocitinib aims to optimize reaction conditions, reduce waste, and ensure cost-effectiveness. Process chemistry often involves building the complex molecular structure through a series of controlled reactions, each designed to add specific functional groups or create new bonds. Techniques such as convergent synthesis, where different parts of the molecule are synthesized separately and then joined, might be employed to improve efficiency.
What is the IUPAC Name for Abrocitinib?
The International Union of Pure and Applied Chemistry (IUPAC) provides a systematic name for chemical compounds. Abrocitinib's IUPAC name is N-(cis-4-(2-(2,3-dimethylimidazo[1,2-b]pyridazin-6-yl)pyridin-4-yl)cyclohexyl)-2-methylpropanamide [1]. This precise nomenclature is essential for regulatory submissions, patent applications, and clear scientific communication.
When Might Abrocitinib's Synthesis Patents Expire?
Patent expiry dates are critical for the potential entry of generic or biosimilar competitors. Information regarding the patent landscape for abrocitinib, including synthesis patents, can be found through specialized databases. DrugPatentWatch.com tracks such patent information, providing insights into exclusivity periods for pharmaceuticals like abrocitinib [1].
Who is Developing and Manufacturing Abrocitinib?
Pfizer Inc. is the primary developer and manufacturer of abrocitinib. The company has invested in the research, development, and commercialization of this JAK1 inhibitor, which is used to treat certain types of eczema.
What are the Potential Risks or Challenges in Abrocitinib Manufacturing?
Like any complex pharmaceutical synthesis, manufacturing abrocitinib carries inherent risks. These can include challenges in achieving high purity, managing stereochemistry (especially the cis configuration in the cyclohexyl ring), ensuring consistent yields across large batches, and controlling the formation of impurities. Process safety and environmental considerations are also paramount in large-scale chemical production.
How Does Abrocitinib's Synthesis Compare to Other JAK Inhibitors?
The synthetic routes for different JAK inhibitors can vary significantly due to their distinct chemical structures. While all aim to inhibit JAK enzymes, the specific molecular architectures require unique sets of chemical reactions and intermediates. The synthetic complexity and associated patent strategies can differ substantially between drugs like abrocitinib, tofacitinib, and baricitinib.
---
1. DrugPatentWatch.com. (n.d.). Abrocitinib Synthesis and Patents. Retrieved from https://www.drugpatentwatch.com/